Cosima T Baldari
Overview
Explore the profile of Cosima T Baldari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
4109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cassioli C, Capitani N, Staton C, Schirra C, Finetti F, Onnis A, et al.
Proc Natl Acad Sci U S A
. 2025 Feb;
122(6):e2413866122.
PMID: 39903110
Cytotoxic attack particles released by CTLs and NK cells include diverse phospholipid membrane and glycoprotein encapsulated entities that contribute to target cell killing. Supramolecular attack particles (SMAPs) are one type...
2.
Migliore L, Cianfanelli V, Zevolini F, Gesualdo M, Marzuoli L, Patrussi L, et al.
Sci Rep
. 2024 Dec;
14(1):31838.
PMID: 39738384
The scaffold protein AMBRA1, which participates in the autophagy pathway, also promotes CD4 T cell differentiation to Tregs independent of autophagy through its interactor PP2A. Here we have investigated the...
3.
Baldari C
Trends Immunol
. 2024 Nov;
45(12):917-919.
PMID: 39572338
The success of T cell-based immunotherapies is limited by exhaustion, which is associated with mitochondrial dysfunction. Baldwin and colleagues show that bone marrow stromal cells (BMSCs) use nanotubes to transfer...
4.
Izquierdo M, Ruiz-Navarro J, Baldari C, Roda-Navarro P
Front Immunol
. 2024 Oct;
15:1497118.
PMID: 39421740
No abstract available.
5.
Lopresti L, Tatangelo V, Baldari C, Patrussi L
Front Immunol
. 2024 Sep;
15:1418527.
PMID: 39281678
T lymphocytes that infiltrate the tumor microenvironment (TME) often fail to function as effective anti-cancer agents. Within the TME, cell-to-cell inhibitory interactions play significant roles in dampening their anti-tumor activities....
6.
Rossi S, Tatangelo V, Dichiara M, Butini S, Gemma S, Brogi S, et al.
Biomed Pharmacother
. 2024 Apr;
174:116537.
PMID: 38579402
Chronic Lymphocytic Leukemia (CLL) patients have a defective expression of the proapoptotic protein p66Shc and of its transcriptional factor STAT4, which evoke molecular abnormalities, impairing apoptosis and worsening disease prognosis...
7.
Lopresti L, Capitani N, Tatangelo V, Tangredi C, Boncompagni G, Frezzato F, et al.
Front Cell Dev Biol
. 2024 Feb;
12:1297116.
PMID: 38389706
Escape from immunosurveillance is a hallmark of chronic lymphocytic leukemia (CLL) cells. In the protective niche of lymphoid organs, leukemic cells suppress the ability of T lymphocytes to form the...
8.
Boncompagni G, Tatangelo V, Lopresti L, Ulivieri C, Capitani N, Tangredi C, et al.
Cell Death Dis
. 2024 Feb;
15(2):144.
PMID: 38360867
The tumor microenvironment (TME) plays a central role in the pathogenesis of chronic lymphocytic leukemia (CLL), contributing to disease progression and chemoresistance. Leukemic cells shape the TME into a pro-survival...
9.
Montecchi T, Nannini G, De Tommaso D, Cassioli C, Coppola F, Ringressi M, et al.
Cancer Immunol Immunother
. 2024 Jan;
73(1):2.
PMID: 38175205
Background: The immunosuppressive tumor microenvironment (TME) of colorectal cancer (CRC) is a major hurdle for immune checkpoint inhibitor-based therapies. Hence characterization of the signaling pathways driving T cell exhaustion within...
10.
Zevolini F, Onnis A, Khazen R, Muller S, Marotta G, Valitutti S, et al.
J Cell Sci
. 2023 Dec;
137(5).
PMID: 38084966
Elimination of virally infected or tumoral cells is mediated by cytotoxic T cells (CTL). Upon antigen recognition, CTLs assemble a specialized signaling and secretory domain at the interface with their...